RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

This publication has 24 references indexed in Scilit:

• Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 gy)
  International Journal of Radiation Oncology*Biology*Physics, 2002
• Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
  International Journal of Radiation Oncology*Biology*Physics, 2001
• Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials
  Journal of Clinical Oncology, 2000
• Dose selection for prostate cancer patients based on dose comparison and dose response studies
  International Journal of Radiation Oncology*Biology*Physics, 2000
• Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406
  International Journal of Radiation Oncology*Biology*Physics, 2000
• Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
  International Journal of Radiation Oncology*Biology*Physics, 1998
• External beam radiotherapy dose response of prostate cancer
  International Journal of Radiation Oncology*Biology*Physics, 1997
• Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
  International Journal of Radiation Oncology*Biology*Physics, 1997
• The effect of dose on local control of prostate cancer
  International Journal of Radiation Oncology*Biology*Physics, 1988
• Tumor control in definitive irradiation of localized carcinoma of the prostate
  International Journal of Radiation Oncology*Biology*Physics, 1986